# Histide

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/histide

- Industry: Biotechnology
- Headquarters: Switzerland
- Website: www.histide.com
- Total disclosed funding: $4.7M
- Latest round: Series A (Nov 10, 2014)
- Investors on record: 1

## About

Histide AG is a biotechnology firm based in Switzerland, focused on developing non-mutagenic extracellular therapeutic agents known as Cell Recoding Molecules™ (CRM™) for treating various diseases, including cancer and metabolic disorders.Founded in 2014 and headquartered in Switzerland, Histide AG is dedicated to biotechnological advancements. The firm has engaged in one deal, securing CHF 4.5 million in a Series A funding round on November 10, 2014, with contributions from PARTER Capital Group and private investors. The CEO of the company is Omar Zouani.Histide™ specializes in the development of innovative non-mutagenic extracellular therapeutic agents known as Cell Recoding Molecules™ (CRM™). These advanced therapeutic solutions leverage the mechanisms of cell microenvironmental sensing and signal transduction to enhance the cell's natural ability to redirect its fate, facilitating a process referred to as Recoding Therapeutics™. This groundbreaking approach enables precise control over cellular behavior without the need for introducing foreign entities into cells, thus minimizing potential harm. Histide's CRM™ technology is designed to target various diseases, including cancer, metabolic disorders, and rare diseases, with applications spanning pharmaceuticals, medical devices, and cosmetics. The company aims to serve a global clientele, focusing on partnerships with pharmaceutical firms and research institutions in markets such as North America, Europe, and Asia, ensuring a robust distribution network for their novel therapeutic solutions.Histide's revenue generation strategy is primarily centered around forming strategic partnerships and collaborations with pharmaceutical companies and research entities. The company engages in direct-to-business transactions, where clients can procure its proprietary CRM™ technologies for integration into their therapeutic developments. These transactions are structured around licensing agreements and research collaborations, wherein clients benefit from access to Histide's extensive intellectual property portfolio and technological advancements. The revenue model includes milestone payments tied to research breakthroughs and clinical progress, along with potential royalties based on the commercial success of therapies developed using Histide's innovative platform. The company's approach fosters a mutually beneficial environment for both Histide and its partners, driving forward the development of advanced therapeutic solutions.Histide AG plans to leverage its recent funding of CHF 4.5 million from its Series A round to further develop its CRM™ technologies and expand into new markets. Specific geographic regions targeted for expansion include North America and Asia, with plans to establish partnerships by the end of 2024. The funding will support the development of upcoming CRM™ products designed for various therapeutic applications, enhancing Histide's market presence and distribution capabilities.

## Funding rounds

- Series A, Nov 10, 2014, $4.7M — PARTER Capital Group

## Investors

- PARTER Capital Group (https://capitalatlas.ai/funds/parter-capital-group) — Series A